PAS
LCTX icon

Point72 Asia (Singapore)’s Lineage Cell Therapeutics LCTX Stock Holding History

Point72 Asia (Singapore)’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$79.1K Sell
46,817
-64,424
-58% -$76.2K 0.01% 486
2025
Q2 		$101K Buy
+111,241
New +$66K 0.02% 472

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asia (Singapore)'s LCTX Position: Q3 2025 in Review

Point72 Asia (Singapore) reduced its Lineage Cell Therapeutics (LCTX) stake by 58% in Q3 2025, selling an estimated $76.2K and leaving 46,817 shares worth $79.1K. The position accounts for 0.01% of the portfolio, ranked #486.

Point72 Asia (Singapore) first reported a position in LCTX in Q2 2025 and has held it in 2 quarters since. The position peaked at $101K in Q2 2025. 112 funds tracked by Wall St. Rank hold LCTX as of Q3 2025.

  • Point72 Asia (Singapore) held 46,817 shares of Lineage Cell Therapeutics worth $79.1K as of Q3 2025.
  • Point72 Asia (Singapore) sold 64,424 Lineage Cell Therapeutics shares in Q3 2025, an estimated $76.2K.
  • Lineage Cell Therapeutics made up 0.01% of Point72 Asia (Singapore)'s portfolio in Q3 2025, its #486 holding.
  • Point72 Asia (Singapore) first reported a position in Lineage Cell Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Point72 Asia (Singapore)'s Lineage Cell Therapeutics position peaked at $101K in Q2 2025.
  • 112 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.